Impact of visual impairment on physical activity in early and late age-related macular degeneration

Manuel Heinemann, Susanne G. Welker, Jeany Q. Li, Maximilian W. M. Wintergerst, Gabrielle N. Turski, Christopher A. Turski, Jan H. Terheyden, Matthias M. Mauschitz, Frank G. Holz, Robert P. Finger*

University of Bonn, Department for Ophthalmology, Ernst-Abbe-Straße, Bonn, Germany

* Robert.Finger@ukbonn.de

Abstract

Background

Modifiable risk factors for age-related macular degeneration (AMD) include smoking, nutrition and likely physical activity (PA). Levels of PA, however, are impacted by any visual impairment which makes the assessment of any association with AMD difficult.

Purpose

To assess the impact of visual impairment under both high and low luminance conditions on levels of PA in early and late AMD.

Methods

Ninety participants with early to late AMD underwent a clinical assessment including conventional best-corrected visual acuity, low luminance visual acuity, contrast sensitivity and the Moorfields acuity test. PA was recorded using a wrist-worn accelerometer (GENEActiv, Activeinsights) on seven consecutive days. Patient characteristics were compared with the Wilcoxon rank-sum test and determinants of moderate-to-vigorous-PA (MVPA) were assessed using linear regression models.

Results

Mean age was 73.9 ± 8.5 years (range 50–89) and 47 subjects (52.2%) were women. Average MVPA time was longer in the early (355.1 ± 252.0 minutes/week) compared to the late AMD group (162.2 ± 134.6 minutes/week; p < 0.001). Using linear regression, age [β = -0.25; 95% confidence interval (CI): -12.9; -0.8, p = 0.028] and AMD stage (β = -0.28; 95% CI: -230.9, -25.0; p = 0.015) but not visual impairment on any of the employed tests were associated with MVPA (minutes/week).
Conclusions
We found late AMD to be associated with reduced PA. As performance on any of the visual tests was not associated with PA, this association cannot entirely be explained by functional impairment. More research is needed to further explore the association of PA and AMD as PA may be a potentially modifiable risk factor.

Introduction
Age-related macular degeneration (AMD) is the main cause of severe visual impairment and blindness in industrialized countries. [1,2] AMD can be classified into early, intermediate and late stage disease. [3] While patients with early and intermediate AMD tend to have no or only little visual impairment, late stage AMD can severely reduce visual acuity and, thus, impact quality of life. [4,5] Known risk factors include age, genetic predisposition, smoking, nutrition and likely physical activity (PA). [6–15]

Moderate to high levels of PA have been described as a protective factor in various diseases [16–21], even if PA is increased only later in life. [22] A systematic review and meta-analysis by McGuiness and colleagues found lower odds of early and late AMD in those with above average levels of PA [11] The Blue Mountains Eye Study reported lower levels of PA in participants with late AMD compared to early, but did not find PA to lower the risk of incident AMD. [6] Conversely, the Beaver Dam Eye Study reported high levels of PA to be protective for incident visual impairment irrespective of underlying pathology. [7] Thus, the status of PA as an AMD risk factor today is controversial and confounded by the visual impairment occurring concurrently with AMD progression. [11,23,24] Most of the studies to date have quantified PA using self-report, i.e. questionnaires, with very few studies employing objective measurements based on e.g. accelerometers (ACCs). [9,25,26]

Herein, we assessed any visual impairment under high and low luminance as well as levels of PA using an accelerometer in persons with various stages of AMD in order to better characterize the relationship of PA, visual impairment and AMD.

Materials and methods
Participants
We enrolled 90 participants aged 50 years and above with a diagnosis of AMD. All patients underwent a dilated fundus exam by an ophthalmologist and multi-modal retinal imaging including infrared reflectance, spectral domain—optical coherence tomography and fluorescein angiography if deemed necessary by the assessing physician (SD-OCT; Spectralis, Heidelberg Engineering). Maximum drusen size and signs of late AMD (atrophy or signs associated with CNV) were determined based on this multi-modal approach. AMD classification was based on the worse eye in accordance with the recently published clinical classification of AMD. [3] Participants were categorized into “early AMD” (including participants with early and intermediate AMD) and "late AMD" based on the more advanced eye and in accordance to the Beckman Initiative for Macular Research Classification Committee. [3]

All patients underwent a standardized interview on demographic factors, medical and ophthalmic history and awareness of eye diseases. Subsequently, participants were clinically assessed and underwent visual function tests. After this, they were equipped with the wrist-
worn ACCs. Assessments took place between January 2017 and January 2019 at the Department of Ophthalmology at the University of Bonn, Germany.

The study was approved by the Institutional Review Board of the University of Bonn, Germany (approval ID: 013/16). Written informed consent was obtained from all participants following the guidelines of the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice (ICH-GCP).

Physical activity measurement
Everyday PA was assessed using the GENEActiv ACC (Activeinsights, Kimbolton, United Kingdom). Participants are required to wear the ACC continuously (i.e. for 24 hours a day) on seven consecutive days including the weekend on their non-dominant wrist. [27] As the devices are waterproof, they do not need to be taken off for any activities involving contact with water. The GENEActiv ACC is based on a microelectronic- mechanic system, which documents acceleration in g in all of the three dimensions (1g = 9,81 m/s²; max. possible acceleration: 8g ± 3,9mg). Frequency of data collection for the seven days was 100 Hz. [28,29] We summarized PA data into minutes per week for sedentary, low, moderate, vigorous and moderate-to-vigorous (MVPA) activity. [27]

Visual function tests
All participants underwent the following best-corrected visual function tests: high-luminance visual acuity (i.e. conventional VA, HLVA), low luminance visual acuity (LLVA) as well as the Moorfields acuity test (MAT) at a standard distance of four meters and recorded the maximum letters. If the patient was unable to read the first four rows of the test, the distance was reduced to one meter. [30] For HLVA and LLVA, Early Treatment Diabetic Retinopathy Study (ETDRS) charts were used in a standard retro-illumination box. After testing HLVA, an additional 2log-unit density filter was placed in the trial frame. The MAT follows the same procedure as HLVA, with a modified test chart based on the ETDRS chart with an additional high pass filter, to simulate lower contrast situations. [31] Subsequently, we performed the Pelli-Robson contrast sensitivity test at a distance of one meter. [32]

Data analysis
Data were recorded electronically using Excel (Version 14.0, Microsoft, Washington, USA). Groups were compared using Wilcoxon rank-sum tests for continuous variables and Mann-Whitney test for categorical variables. Determinants of MVPA were assessed using linear regression models. Analyses were performed with STATA 13 (StataCorp, College Station, USA). P-values below 0.05 were considered statistically significant.

Results
Mean (SD) age of the 90 participants was 73.9 ± 8.5 years (range 50–89) and 47 subjects were women. Patients with early AMD were on average younger than those with late neovascular AMD and had a higher MVPA (p<0.001, Table 1). BMI was not different between early and late AMD (p = 0.23).

Visual functional tests
Participants in the early AMD group, overall performed better on all functional tests compared with the late AMD group (p<0.001; Table 2).
Determinants of PA

Assessing determinants of MVPA irrespective of any AMD classification, both age ($\beta = -0.28; 95\% \text{ CI}: -13.3; -1.7, p = 0.012$) and LLVA ($\beta = 0.27; 95\% \text{ CI}: 0.6; 5.5, p = 0.016$) were independently associated (Table 3). Including AMD status into the model, we found age ($\beta = -0.25; 95\% \text{ CI}: -12.9; -0.8, p = 0.028$) and AMD stage ($\beta = -0.28; 95\% \text{ CI}: -230.9; -25.0, p = 0.015$) to be determinants of MVPA, while performance on none of the functional tests remained associated (Table 4). Assessing determinants of MVPA in early and late AMD separately, HLVA was associated with MVPA in the early AMD group only (OR = 1.45; 95% CI 3.34; 23.45).

Discussion

In this study we found age and stage of AMD to be determinants of MVPA, which was much lower in participants with late AMD. LLVA was the only functional outcome associated with MVPA across the whole sample, but no functional tests remained associated after controlling for AMD stage and age. Thus, the association of AMD stage and MVPA cannot entirely be explained by functional loss. More research is needed to clarify the association of PA and AMD as PA may be a potentially modifiable AMD risk factor.

Higher levels of vigorous exercise have been reported to be associated with reduced incident risk for any AMD [33] and early AMD. [11] In cross-sectional studies, late AMD was consistently associated with lower levels of PA. [9,34] However, study comparisons are limited as most studies have used different questionnaires[6,8,10,24,35,36] or one- to three-dimensional

### Table 1. Participant characteristics.

| Characteristics | n (%) or mean ± SD |
|-----------------|-------------------|
|                 | all | early AMD | late AMD | p-value |
| n (%)           | 90 (100%) | 49 (54.4%) | 41 (45.6%) | <0.001 |
| Age (in years)  | 73.9 ± 8.5 | 69.6 ± 7.8 | 79.1 ± 6.0 | <0.001 |
| Range (in years)| 50–89 | 50–84 | 63–89 | |
| Sex Male        | 43 (47.8%) | 17 (34.7%) | 16 (39%) | 0.67 |
| Female          | 47 (52.2%) | 32 (65.3%) | 25 (61%) | |
| BMI (kg/m²)     | 25.6 ± 3.3 | 26.8 ± 4.7 | 26.8 ± 4.7 | 0.23 |
| MVPA (min/week) | 355.1 ± 252.0 | 162.2 ± 134.6 | 162.2 ± 134.6 | <0.001 |

SD = standard deviation BMI = body mass index; MVPA = moderate-to-vigorous-activity (minutes per week)

https://doi.org/10.1371/journal.pone.0222045.t001

### Table 2. Performance on visual function tests.

| Statistic | early AMD | late AMD | p-value * |
|-----------|-----------|----------|-----------|
| HLVA      | Mean ± SD | 82.8 ± 6.9 | 54.2 ± 15.9 | <0.001 |
| Min; Median; Max | 62 ; 84 ; 95 | 12 ; 58 ; 79 |
| LLVA      | Mean ± SD | 65.9 ± 9.6 | 35.4 ± 16.0 | <0.001 |
| Min; Median; Max | 40 ; 68 ; 85 | 0 ; 38 ; 68 |
| MAT       | Mean ± SD | 61.1 ± 6.9 | 38.9 ± 12.6 | <0.001 |
| Min; Median; Max | 48 ; 62 ; 79 | 0 ; 42 ; 60 |
| Pelli-Robson | Mean ± SD | 34.1 ± 3.6 | 24.8 ± 7.6 | <0.001 |
| Min; Median; Max | 20 ; 34 ; 42 | 0 ; 28 ; 35 |

*Wilcoxon rank-sum test; SD = standard deviation; HLVA = high luminance best-corrected visual acuity; LLVA = low-luminance visual acuity; MAT = Moorfields Vanishing Optotypes Acuity Test, Pelli-Robson = Pelli Robson contrast sensitivity

https://doi.org/10.1371/journal.pone.0222045.t002
non-waterproof ACCs \([9,25,26,34]\) to quantify PA. Questionnaires have been shown to overestimate PA, with objective means to quantify PA such as accelerometers yielding lower levels of PA compared to questionnaires. \([28]\) Non-waterproof ACCs need to be taken off for any activity involving contact with water, which likely includes any household cleaning activity, so is likely to considerably underestimate PA. \([37]\) Taking this into consideration, our results using a waterproof, wrist-worn ACCs are likely to be representative of actual levels of PA. Overall results are in keeping with other published studies, reporting lower levels of PA in late AMD compared to earlier stages of the disease and controls. \([9,26,34]\)

Compared to previous studies, which used a number of existing or self-developed AMD classification systems \([6,9,35]\), we classified AMD according to the recently published Beckettmann classification system. \([3]\) Some studies did not discriminate AMD stages at all. \([34]\) This somewhat limits comparability between studies. However, there is growing evidence that classification into early stages (comprising early and intermediate AMD according to the Beck-mann classification) and late AMD is very comparable across different AMD classification systems. \([31,38,39]\)

Furthermore, the assessments of visual impairment differed substantially between studies with most studies assessing only HLVA. For instance, participants of the National Health and Nutrition Examination Surveys were categorized based on HLVA measured with an autorefractor regardless of the underlying disease.\([26]\) As a consequence, these and other studies did not consider comparable outcomes in HLVA or other functional tests as was done in our study and might have missed associations between specific visual impairment under low luminance or low contrast situations, PA and AMD. Given our results, however, any study assessing these associations should quantify both visual impairment and PA objectively.

We found, PA to be lower with increasing age and/or presence of late AMD. Other studies using ACCs also identified visual impairment as the main factor for reduced MVPA in late AMD. \([9,34]\) We did not find performance on any of the employed visual function tests to be associated with MVPA when including AMD stage in the model, which might be due to a difference in visual function between the early and late stage participants. Assessing the association of visual function and MVPA irrespective of AMD stage, we found LLVA to be associated. This is of particular interest as function under low luminance seems to be first and foremost affected in early AMD stages, as is reflected in our sample as well. \([40,41]\) This

### Table 3. Determinants of MVPA irrespective of AMD status.

|         | Beta coefficient | 95% Conf. Interval | p-value<sup>*</sup> |
|---------|------------------|--------------------|---------------------|
| Age     | -0.28            | -13.3, -1.7        | 0.012               |
| LLVA    | 0.27             | 0.6, 5.5           | 0.016               |

* Multivariate linear regression model, MVPA = moderate-to-vigorous physical activity, AMD = Age-related macular degeneration, LLVA = low-luminance visual acuity

https://doi.org/10.1371/journal.pone.0222045.t003

### Table 4. Determinants of MVPA including AMD status.

|         | Beta coefficient | 95% Conf. Interval | p-value<sup>*</sup> |
|---------|------------------|--------------------|---------------------|
| Age     | -0.25            | -12.9, -0.8        | 0.028               |
| AMD stage | -0.28          | -230.9, -25.0      | 0.015               |

* Multivariate linear regression model, MVPA = moderate-to-vigorous physical activity, AMD = Age-related macular degeneration

https://doi.org/10.1371/journal.pone.0222045.t004
finding—the association of any visual impairment with PA—is in keeping with the aforementioned studies also employing ACCs. [9,26,34]

Strengths of our study included the use of a three-dimensional waterproof ACC, which allows for a continuous measurement of PA at all times and during all conditions. Assessing PA by ACC can lead to increased levels of PA because of the constant “monitoring” of participants. [42] However, this is unlikely to affect recorded levels of PA more than the very common over-reporting of PA when using questionnaires. Further strengths of our study are the meticulous phenotyping and comprehensive assessment of any present visual impairment, in particular under low luminance and low contrast conditions which is highly relevant to AMD. Limitations include the cross-sectional nature of our study and the moderate sample size. However, using an ACC reduces the sample size needed compared to the less precise quantification of PA using questionnaires. Cut-offs for the duration of PA measurement are somewhat arbitrary and might lead to some PA relevant to the research question not being captured. However, we demonstrated that capturing PA over 30 versus 7 days did not yield any more useful data in relation to average weekly PA in a comparable group of older persons with eye diseases, which is why we chose to capture PA over 7 days in this study. [28] This of course does not account for seasonal, event-related or weather-related variations in PA. Participants were instructed to switch the ACCs on if they had a “normal” week ahead of them, without any variation to their normal PA routine which might have led to a measurement approximating the true mean of their weekly PA somewhat better. However, we have no means of verifying this. As we did not include an age-matched control group without AMD, our results cannot be transferred to a general older population. AMD patients experiencing impairment in central visual function may adapt to vision loss and compensate by using e.g. eccentric fixation. We did not capture adaptation to vision loss other than through participants’ performance in tests of central visual function. Whether adaptation to vision loss is relevant for individual PA levels over and above this needs to be assessed by future studies. We did not find lifestyle factors such as smoking to be associated with MVPA in our sample which is likely due to only a small number of smokers. Similarly, we were not able to assess the impact of concurrent other disabilities on MVPA as only two participants reported any additional disability not related to vision.

The lack of association found once we controlled for AMD stage might be explained by a clear separation into visual performance levels by AMD stage. Furthermore, the applied ACCs have not been validated against other objective measures of PA in AMD patients. Elderly, particularly visually impaired persons may have difficulties in handling the devices which may confound the measured PA. In a previous study, we evaluated the applicability of the same ACCs in an older population with eye diseases. We found a high acceptance and participants were generally able to handle the devices correctly. [28] However, the literature regarding PA measurements in older populations, in particular those with vision impairment, is sparse and no studies specifically assessing the validity of any PA measurements against performance in a lab have been published for this group.

In conclusion, we found AMD stage, but not performance in any functional test to be associated with MVPA in our cohort. Thus, the association of AMD stage and MVPA cannot entirely be explained by functional loss in late AMD. Further longitudinal research is needed to further clarify the association of PA and AMD.

**Author Contributions**

**Conceptualization:** Robert P. Finger.

**Data curation:** Manuel Heinemann.
Formal analysis: Manuel Heinemann.

Investigation: Manuel Heinemann, Susanne G. Welker, Jeany Q. Li, Maximilian W. M. Wintergerst, Gabrielle N. Turski, Christopher A. Turski, Jan H. Terheyden, Matthias M. Mauschitz, Robert P. Finger.

Methodology: Robert P. Finger.

Project administration: Robert P. Finger.

Supervision: Frank G. Holz.

Writing – original draft: Manuel Heinemann.

References

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012; 379: 1728–1738. https://doi.org/10.1016/S0140-6736(12)60282-7 PMID: 22559899

2. Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018. https://doi.org/10.1136/bjophthalmol-2017-311258 PMID: 2954517

3. Ferris FL3, Wilkinson CP, Bird A, Chakravarty U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120: 844–851. https://doi.org/10.1016/j.ophtha.2012.10.036 PMID: 23332590

4. Fenwick EK, Cheung GCM, Gan AT, Tan G, Lee SY, Wong D, et al. Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration. Br J Ophthalmol. 2018; 102: 377–382. https://doi.org/10.1136/bjophthalmol-2017-310532 PMID: 28659392

5. Finger RP, Fenwick E, Marella M, Dirani M, Holz FG, Chiang PP-C, et al. The impact of vision impairment on vision-specific quality of life in Germany. Invest Ophthalmol Vis Sci. 2011; 52: 3613–3619. https://doi.org/10.1167/iovs.10-7127 PMID: 21357395

6. Gopinath B, Liew G, Burlutsky G, Mitchell P. Physical activity and the 15-year incidence of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014; 55: 7799–7803. https://doi.org/10.1167/iovs.14-15575 PMID: 25389200

7. Klein R, Lee KE, Gangnon RE, Klein BEK. Relation of smoking, drinking, and physical activity to changes in vision over a 20-year period: the Beaver Dam Eye Study. Ophthalmology. 2014; 121: 1220–1228. https://doi.org/10.1016/j.ophtha.2014.01.003 PMID: 24594095

8. Knudston MD, Klein R, Klein BEK. Physical activity and the 15-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Br J Ophthalmol. 2006; 90: 1461–1463. https://doi.org/10.1136/bjo.2006.103796 PMID: 17077116

9. Loprinzi PD, Swenor BK, Ramulu PY. Age-Related Macular Degeneration Is Associated with Less Physical Activity among US Adults: Cross-Sectional Study. PLoS One. 2015; 10: e0125394. https://doi.org/10.1371/journal.pone.0125394 PMID: 25933421

10. McGuinness MB, Karahalios A, Simpson JA, Guynner RH, Robman LD, Hodge AM, et al. Past physical activity and age-related macular degeneration: the Melbourne Collaborative Cohort Study. Br J Ophthalmol. 2016; 100: 1353–1358. https://doi.org/10.1136/bjophthalmol-2015-307663 PMID: 26787681

11. McGuinness MB, Le J, Mitchell P, Gopinath B, Cerin E, Saksens NTM, et al. Physical Activity and Age-related Macular Degeneration: A systematic literature review and meta-analysis. Am J Ophthalmol. 2017. https://doi.org/10.1016/j.ajo.2017.05.016 PMID: 28549846

12. Colijn JM, den Hollander Al, Demirkan A, Cougnard-Gregoire A, Verzijden T, Kersten E, et al. Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia. Ophthalmology. 2018. https://doi.org/10.1016/j.ophtha.2018.09.045 PMID: 30315903

13. Raimundo M, Mira F, Cachulo MdL, Barreto P, Ribeiro L, Farinha C, et al. Adherence to a Mediterranean diet, lifestyle and age-related macular degeneration: the Coimbra Eye Study—report 3. Acta Ophthalmol. 2018. https://doi.org/10.1111/aos.13775 PMID: 30218481

14. Smith W, Mitchell P. Family history and age-related maculopathy: The Blue Mountains Eye Study. Australian and New Zealand Journal of Ophthalmology; 26: 203–206. https://doi.org/10.1111/j.1442-9071.1998.tb01311.x PMID: 9717749
15. AgeRelated_Eye_Disease_Study_Research_Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001; 119: 1417–1436. https://doi.org/10.1001/archophthalmol.119.10.1417 PMID: 11594942

16. Paffenbarger RS, JR, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med. 1986; 314: 605–613. https://doi.org/10.1056/NEJM198603063141003 PMID: 3945246

17. Johnson R, Robertson W, Towey M, Stewart-Brown S, Clarke A. Changes over time in mental well-being, fruit and vegetable consumption and physical activity in a community-based lifestyle intervention: a before and after study. Public Health. 2017; 146: 118–125. https://doi.org/10.1016/j.puhe.2017.01.012 PMID: 28404463

18. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017; 18: e457–e471. https://doi.org/10.1016/S1470-2045(17)30411-4 PMID: 28793985

19. Loprinzi PD, Pariser G, Ramulu PY. Accelerometer-assessed sedentary and physical activity behavior and its association with vision among U.S. adults with diabetes. J Phys Act Health. 2014; 11: 1156–1161. https://doi.org/10.1123/jpah.2012-0354 PMID: 24184561

20. McMahon EM, Corcoran P, O’Regan G, Keeley H, Cannon M, Carli V, et al. Physical activity in European adolescents and associations with anxiety, depression and well-being. Eur Child Adolesc Psychiatry. 2017; 26: 111–122. https://doi.org/10.1007/s00787-016-0875-9 PMID: 27277894

21. Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2015; 30: 529–542. https://doi.org/10.1038/ejepsi.2015.188 PMID: 26092138

22. Hamer M, Lavoie KL, Bacon SL. Taking up physical activity in later life and healthy ageing: the English longitudinal study of ageing. Br J Sports Med. 2014; 48: 239–243. https://doi.org/10.1136/bjsports-2013-092993 PMID: 24276781

23. McGuinness MB, Finger RP, Karahalios A, Guymer RH, English DR, Chong EW, et al. Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study. Eye (Lond). 2017; 31: 1345–1357. https://doi.org/10.1038/eye.2017.139 PMID: 28820184

24. Subhi Y, Sorensen TL. Physical activity patterns in patients with early and late age-related macular degeneration. Dan Med J. 2016; 63.

25. Nguyen AM, Arora KS, Snover BK, Friedman DS, Ramulu PY. Physical activity restriction in age-related eye disease: a cross-sectional study exploring fear of falling as a potential mediator. BMC Geriatr. 2015; 15: 64. https://doi.org/10.1186/s12877-015-0062-8 PMID: 26062727

26. Willis JR, Jefferys JL, Vitale S, Ramulu PY. Visual impairment, uncorrected refractive error, and accelerometer-defined physical activity in the United States. Arch Ophthalmol. 2012; 130: 329–335. https://doi.org/10.1001/archophthalmol.2011.1773 PMID: 22411662

27. Dillon CB, Fitzgerald AP, Kearney PM, Perry IJ, Kozarski R, et al. Number of Days Required to Estimate Habitual Activity Using Wrist-Worn GENEA Accelerometer: A Cross-Sectional Study. PLoS One. 2016; 11: e0109913. https://doi.org/10.1371/journal.pone.0109913 PMID: 27149674

28. Heinemann M, Welker SG, Holz FG, Finger RP. Physical activity in older persons with eye diseases. Applicability of wrist-worn accelerometer. Ophthalmologie. 2018. https://doi.org/10.1007/s00347-018-0688-y PMID: 29564538

29. Esliger DW, Rowlands AV, Hurst TL, Catt M, Murray P, Eston RG. Validation of the GENEA Accelerometer. Med Sci Sports Exerc. 2011; 43: 1085–1093. https://doi.org/10.1249/MSS.0b013e31820513be PMID: 21088628

30. Ferris FL3, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982; 94: 91–96. PMID: 7091289

31. Shah N, Dakin SC, Dobinson S, Tufail A, Egan CA, Anderson RS. Visual acuity loss in patients with age-related macular degeneration measured using a novel high-pass letter chart. Br J Ophthalmol. 2016; 100: 1346–1352. https://doi.org/10.1136/bjophthalmol-2015-307375 PMID: 26846435

32. Elliott DB, Sanderson K, Conkey A. The reliability of the Pelli-Robson contrast sensitivity chart. Ophthalmic Physiol Opt. 1990; 10: 21–24. PMID: 2330208

33. Williams PT. Prospective study of incident age-related macular degeneration in relation to vigorous physical activity during a 7-year follow-up. Invest Ophthalmol Vis Sci. 2009; 50: 101–106. https://doi.org/10.1167/iovs.08-2165 PMID: 18566466

34. Sengupta S, Nguyen AM, van Landingham SW, Solomon SD, Do DV, Ferrucci L, et al. Evaluation of real-world mobility in age-related macular degeneration. BMC Ophthalmol. 2015; 15: 9. https://doi.org/10.1186/1471-2415-15-9 PMID: 25636376
35. Munch IC, Linneberg A, Larsen M. Precursors of age-related macular degeneration: associations with physical activity, obesity, and serum lipids in the inter99 eye study. Invest Ophthalmol Vis Sci. 2013; 54: 3932–3940. https://doi.org/10.1167/iovs.12-10785 PMID: 23652489

36. Rim TH, Kim HK, Kim JW, Lee JS, Kim DW, Kim SS. A Nationwide Cohort Study on the Association Between Past Physical Activity and Neovascular Age-Related Macular Degeneration in an East Asian Population. JAMA Ophthalmol. 2018; 136: 132–139. https://doi.org/10.1001/jamaophthalmol.2017.5682 PMID: 29242918

37. Adjei NK, Brand T. Investigating the associations between productive housework activities, sleep hours and self-reported health among elderly men and women in western industrialised countries. BMC public health. 2018; 18: 110. https://doi.org/10.1186/s12889-017-4979-z PMID: 29320997

38. Wu Z, Ayton LN, Luu CD, Guymer RH. Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration. JAMA Ophthalmol. 2015; 133: 442–448. https://doi.org/10.1001/jamaophthalmol.2014.5963 PMID: 25632841

39. Dimitrov PN, Robman LD, Varsamidis M, Aung KZ, Makeyeva GA, Guymer RH, et al. Visual function tests as potential biomarkers in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011; 52: 9457–9469. https://doi.org/10.1167/iovs.10-7043 PMID: 22003115

40. Wu Z, Guymer RH, Finger RP. Low luminance deficit and night vision symptoms in intermediate age-related macular degeneration. Br J Ophthalmol. 2016; 100: 395–398. https://doi.org/10.1136/bjophthalmol-2015-306621 PMID: 26250520

41. Chandramohan A, Stinnett SS, Petrowski JT, Schuman SG, Toth CA, Cousins SW, et al. Visual function measures in early and intermediate age-related macular degeneration. Retina. 2016; 36: 1021–1031. https://doi.org/10.1097/IAE.0000000000001002 PMID: 26925951

42. Hartman SJ, Nelson SH, Weiner LS. Patterns of Fitbit Use and Activity Levels Throughout a Physical Activity Intervention: Exploratory Analysis from a Randomized Controlled Trial. JMIR Mhealth Uhealth. 2018; 6: e29. https://doi.org/10.2196/mhealth.8503 PMID: 29402761